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Summary Pancreatic cancer is difficult to treat, even for tumours localized to the pancreas. Photodynamic therapy (PDT) is a non-thermal
technique for producing localized tissue necrosis with light after prior administration of a photosensitizing drug and it could have a role in the
local treatment of these cancers. We studied PDT in a transplanted cancer in the hamster pancreas using the photosensitizer mTHPC (meta-
tetrahydroxyphenylchlorin). Fluorescence microscopy showed maximum levels of mTHPC in normal pancreas 2-4 days after sensitization
and in tumour at 4-5 days. For PDT, animals were given 0.1 or 0.3 mg kg-' mTHPC and the tumour was treated at laparotomy 2 or 4 days
later with red light (50 J at 650 nm, continuous orfractionated) delivered via a single fibre touching the tumour surface. The maximum zone of
tumour necrosis (seen 3 days after PDT) was 8.7 mm in diameter with continuous irradiation, increasing to 12.4 mm with light fractionation
(fourequal fractions with 3 min between fractions). The main complication was sealed duodenal perforation, seen in 3 of 16 animals, probably
due to inadequate shielding of the duodenum from the light. The duodenal problems seen in hamsters are unlikely to cause trouble in the
much thicker human duodenum. PDT tumour necrosis in this animal model has now been shown with a range of photosensitizers, but
mTHPC is attractive as it is likely to produce the largest volumes of necrosis around each treatment point with short light exposure times. This
technique could have a role in the treatment of localized cancers of the pancreas in patients unsuitable for surgery and can now be
considered for preliminary clinical trials.
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Pancreatic cancer is one of the commonest malignancies and
carries a very poor prognosis, with only 1-2% of patients
surviving 5 years. Radiotherapy and chemotherapy may give some
worthwhile palliation, but the benefit is not great and radical
surgery is rarely beneficial. One of the new methods currently
being explored experimentally for treating this cancer is photo-
dynamic therapy (PDT). PDT is a non-thermal technique that
involves the local activation of a preadministered photosensitizer
by light of wavelength matched to an absorption peak of the
photosensitizer being used. Ideally, such agents would be selec-
tively retained in the tumour compared with the surrounding
normal tissue. In practice, the levels of selectivity between most
tumours and the normal tissue in which they arose is inadequate,
and it is difficult to achieve therapeutic selectivity upon light acti-
vation. Some degree of normal tissue damage has to be expected,
but this is acceptable ifhealing can proceed safely without risk to
structure or function ofthe normal tissues (Bown, 1990).
Although pancreatic cancer has yet to be treated with PDT in
humans, experimental studies have been carried out on pancreatic
tumour models in hamsters and rats (Mang and Wiemann, 1987;
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Schroder et al, 1988; Chatlani et al, 1992; Evrard et al, 1994;
Regula et al, 1994). Several photosensitizing agents have been
studied. Most work has been done with haematoporphyrin deriva-
tive (HpD) and its partly purified derivatives, dihaematoporphyrin
ether (DHE) and Photofrin, all of which are rather poorly defined
mixtures ofporphyrins and have the considerable disadvantage of
causing skin photosensitivity that can last up to 2-3 months
(Dougherty et al, 1990). PDT using DHE will produce necrosis in
a chemically induced pancreatic cancer in hamsters, but at the
price ofduodenal perforation (Schroeder et al, 1988). The same is
true for aluminium-sulphonated phthalocyanine (AlSPc) (Nuutinen
et al, 1991; Chatlani et al, 1992) and pheophorbide A (Evrard et al,
1994). 5-Aminolaevulinic acid (ALA)-induced porphyrin sensiti-
zation looks promising, as up to 8 mm ofnecrosis has been seen in
hamster pancreas tumours (Regula et al, 1994), and normal tissues
tolerate the treatment well (Ravi et al, 1996).
Currently, one ofthe photosensitizers that is attracting particular
interest is meta-tetrahydroxyphenyl chlorin (mTHPc), which was
developed at Queen Mary & Westfield College, London, UK,
(Berenbaum et al, 1986, 1993; Bonnett et al, 1989) and was used
in the present study. The tumoricidal effects have been studied in
BALBc nude mice bearing human malignant mesothelioma
xenografts (Chevretton et al, 1992; Ris et al, 1993). The depth of
necrosis was measured in both the tumour and in normal skin and
muscle of the hind leg. PDT necrosis occurred in normal tissue at
intervals between 4 h and 3 days from the sensitization to the light
exposure and in tumours at time intervals from 12 h to 4 days. The
therapeutic ratio between PDT effects on tumour and normal
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Figure 1 Fluorescence intensity in normal acinar pancreas, normal
pancreatic duct and pancreatic cancer as a function of time after 1.0 mg kg-'
mTHPC. The first point recorded was taken 1 h after sensitization
tissue varied significantly with the time interval between sensitiza-
tion and light exposure and was best at 3 days; however, these
studies have been criticized as they did notcompare tumoureffects
with effects in the normal tissue in which the tumour arose, but
rather in quite different normal tissues.
In preliminary clinical studies (Ris et al, 1991), this photosensi-
tizer has been taken up preferentially, with up to 14 times more
uptake in mesothelioma than in skin and other normal tissues;
however, again, no data were given on the uptake in the relevant
normal tissue, which was pleura. Patients had to avoid sunlight for
about 10 days compared with at least 1 month after HpD. In the
first clinical studies in oesophageal and bronchial tumours, it has
proven to be a potent photosensitizer, requiring much lower light
doses and hence shorter treatment times than with other photo-
sensitizers (Savary et al, 1995).
Our previous studies looked at the pharmacokinetics and PDT
effects with mTHPc on the pancreas and adjacent tissues
(duodenum, stomach, bile duct and major blood vessels) in
hamsters (Mlkvy etal, 1996). The results were similar to those seen
with DHE and AlSPc. Lesions in most areas healed safely, but the
one serious problem was perforation of the duodenum (sealed or
free); this occurred in many animals for which the treatment site
had been close to the duodenum. As with AlSPc, this could be
avoided by shielding the duodenum during light exposure, and it is
considered less likely to be a problem in the much thicker human
duodenum. Our preliminary studies and those of others in other
organs have suggested that PDT with mTHPC can produce larger
zones of necrosis with smaller light doses than can be achieved
with alternative photosensitizers (Dilkes et al, 1996); hence the
current experiments were undertaken to assess the potential ofPDT
with mTHPC fortreating cancers in the hamster pancreas.
MATERIALS AND METHODS
Tumour model and photosensitizer
The animals used were female Syrian golden hamsters (100-
120 g). Under general anaesthesia from intramuscular Hypnorm
(Fentanyl and Fluanisone, Janssen Pharmaceuticals), a laparotomy
was performed and 107 cells from the pancreatic carcinoma cell
line PC-I (obtained from the Eppley Institute, Omaha, NB, USA)
were injected directly into the gastric lobe ofthe pancreas as previ-
ously described (Regula et al, 1994). This line was originally
derived from a hamster pancreatic cancer induced by N-nitrosobis
(2-oxopropyl) amine (BOP). This technique yields tumour-bearing
animals much faster than primary tumour induction, but the
tumourretains the histological, biological and antigenic character-
istics of a primary ductal carcinoma and is very similar to the
human disease (Egami et al, 1989; Takiyama et al, 1990). A
further laparotomy was carried out 3 weeks later and a tumour was
detected at the site of injection in the pancreas in about 75% of
animals, with a mean tumour diameter of 1.3 ± 0.7 cm.
The photosensitizer used was mTHPC, which was supplied by
Scotia Pharmaceuticals (Guildford, UK) as a crystalline solid and
dissolved in a solution composed of 20% ethanol, 30% poly-
ethylene glycol 400 and 50% distilled water.
Fluorescence microscopy
Fluorescence microscopy was used to localize the distribution of
mTHPC in normal pancreas and in the transplanted cancers. In
animals confirmed to have pancreatic tumours at the laparotomy
performed 3 weeks after transplantation, 1 mg kg-1 mTHPC was
injected into the inferior vena cava. The higher dose of mTHPC
was used to ensure adequate tissue levels for more accurate fluo-
rescent measurements (Mlkvy et al, 1996). Animals were killed
after 1 and 4 h and 1, 2, 3, 4, 5 and 6 days, and the cancer and
normal pancreas were removed and immediately frozen in a bath
of isopenthane (BDH, UK) cooled in liquid nitrogen. Frozen
sections (10 ,u) were cut (Cryostat E microtome, Reichert) and
stored at -70°C. Two animals were used for each time point and
three sections were taken from each tissue sample. Control
sections were taken from unsensitized animals. An inverted micro-
scope (IMT-2, Olympus) with epifluorescence and phase contrast
attachments (lOx objective) and with a slow scan, cryogenically
cooled, charge-coupled device camera (CCD, Wright Instruments,
Cambridge, UK) was used to obtain fluorescence images of the
selected area ofthe section.
Measurements were made from the tumours and from normal
acinar and ductal regions within the same pancreas, as previously
carried out with ALA-induced endogenous porphyrin sensitization
(Regula et al, 1994). Fluorescence excitation was performed with
a 1.8 mW helium-neon laser operating at 543 nm with the output
directedthrough a liquid light guide (via a 10 nm bandpass filterto
remove extraneous light) onto a dichroic mirror in the epifluores-
cence microscope that incorporated phase-contrast attachments.
Fluorescence was detected in the range 630-680 nm using a
combination of bandpass (Omega Optical) and longpass (Schott
RG595) filters. The values of mean fluorescence intensities were
calculated by image processing software (Wright Instruments)
within rectangular areas of variable size corresponding to regions
of interest. Estimated errors in the photometric readings are
± 15%. No fluorescence photobleaching was evident under the
conditions used. The sections used for fluorescence microscopy
were subsequently stained with haematoxylin and eosin (H&E) for
later visual comparison using light microscopy and photography.
Photodynamic therapy
The light source used was a pulsed (12 kHz) copper vapour-
pumped dye laser (Oxford Lasers, Oxford, UK) at a wavelength of
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Figure 2 (A) Fluorescence image of pancreatic cancer and normal
pancreas 5 days after 1.0 mg kg-' mTHPC. Fluorescence is slightly higher in
the cancer (Ca) than in the adjacent normal pancreas (P) but in both is much
higher than in the associated stroma (S). The fluorescence is quantified in
the colour bar at the top (strongest is white, weakest is black). Scale:
880gm x 550gim. (B) The same section stained with haematoxylin and eosin
Table 1 Mean diameter of zone of necrosis in transplanted cancers 3 days
after PDT (50 mW for 1000 s, 50 J). There were two animals for each set of
treatment values, and all were treated with duodenal shielding
mTHPC dose Day of Type of Size of necrosis Complications
(mg kg-1) PDT treatment (mm)
SP BDO DD
0.1 2 Continual 4.2-4.7 - - -
0.3 2 Continual 5.9-6.2 1 1
0.3 2 3 x 1-min break 7.6-7.9 - - -
0.3 2 3 x 3-min break 8.1-8.4 la 1
0.1 4 Continual 6.1-6.4
0.3 4 Continual 8.3-8.7 - 1 1
0.3 4 3x 1-min break 11.4-11.7 - - 1
0.3 4 3 x 3-min break 11.8-12.4 1a. 1
aDied before planned day of sacrifice. SP, sealed duodenal perforation; BDO,
bile duct obstruction; DD, duodenal diverticula.
Figure 3 Photomicrographs of tumour nodules (see arrows) treated 3 days
previously with a total light dose of 50 J (50 mW for 1000 s), 4 days after
0.3 mg kg-' mTHPC. (A) Continuous light. (B) Fractionated light (four equal
fractions with a 3-min break between fractions). Scale: 20 x 13 mm
650 nm, which corresponds to the main red absorption peak of
mTHPC. Light was delivered via a single 200-pm fibre positioned
at laparotomy just touching the surface of the tumour. The laser
power used was 50 mW as previous work had shown that higher
powers caused thermal effects (Mlkvy et al, 1996). Because ofthe
duodenal perforations seen in our previous experiments on the
normal pancreas, the duodenum was shielded from the therapeutic
light using a small piece ofopaque paper (Nuutinen et al, 1991).
The dose ofmTHPC used was either 0.1 or 0.3 mg kg-1 given 2
or 4 days before PDT. Only one site was treated in each tumour
with a total delivered light dose of 50 J (50 mW for 1000 s). The
light was delivered either in a single fraction or in four equal frac-
tions separated by three breaks ofeither 1 or 3 min. The latter was
done to look forenhancement ofthe PDT effect without increasing
the total light dose, as has been shown using ALA (Messman et al,
1995). All animals were killed 3 days after PDT (known to be the
time ofmaximum necrosis, Mlkvy et al, 1996).
Immediately after killing the animals, the dimensions of the
maximum area of necrosis in the treated tumour were measured
macroscopically and the mean diameter was calculated. Careful
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examination was made to check for evidence of duodenal perfora-
tion, bile duct obstruction or any other abnormalities in the
pancreas or adjacent organs. The relevant tissues were then fixed
and sectioned for histological examination.
RESULTS
Fluorescence microscopy
The results are shown in Figure 1. The highest levels of mTHPC
fluorescence were seen 4-5 days after sensitization in both normal
pancreas and in tumour, and the absolute levels were about the
same in each (Figure 2). Up to 2 days, levels were slightly higher
in the pancreatic duct than in the acinar pancreas, but beyond 3
days this was reversed. Tumour levels only started rising rapidly
on the third day.
Photodynamic therapy
On the basis of the fluorescence studies, most treatments were
carried out at 4 days, but treatments were also done at 2 days to see
if the extent of PDT necrosis could be correlated with the tumour
levels of mTHPC. The results are shown in Table 1. With treat-
ment at either 2 or 4 days, the lesions found using 0.3 mg kg-'
were largerthan those using 0.1 mg kg-' mTHPC and, for the same
dose of mTHPC, the lesions treated at 4 days were larger than
those treated at 2 days. Fractionating the light with three breaks of
either 1 or 3pnin also produced up to 40% larger lesions for the
same total light dose delivered. The number of animals studied
was small, but the lesion size was slightly larger with the 3-min
breaks than with the 1-min breaks.
Using the shielded duodenum technique, the incidence of
complications was low. None was seen using 0.1 mg kg-' mTHPC.
Details of sealed duodenal perforations, bile duct obstruction and
duodenal diverticula in experiments with the higher dose of
0.3 mg kg-' are shown in Table 1. The diverticula were 10-12
small diverticula about 2 mm in diameter. The complications were
greater in animals treated with fractionation of the light, possibly
because ofthe increased treatment time with the greater risk of the
duodenal shielding slipping. The only two animals to die before the
planned day of sacrifice were treated with 3 x 3-min breaks, and
both were found to have sealed duodenal perforations. One other
animal had a sealed duodenal perforation, four had a dilated bile
duct (without evidence of free perforation) and two had multiple
small diverticula in the duodenum. No effects were seen in the
stomach or major blood vessels (aorta, vena cava and portal vein).
Histologically, the treated tumours showed zones of necrosis,
oftenhaemorrhagic in the centre, sharply demarcated from adjacent
viable tumour or normal pancreas and up to 12 mm in diameter
with an inflammatory infiltrate in the surrounding area (Figure 3).
DISCUSSION
This study has shown that it is possible to produce zones of
necrosis up to 12 mm in diameter in tumours in the hamster
pancreas using PDT with mTHPC. The main complication was
sealed perforation of the duodenum, which was seen in 3 of 16
tumour-bearing animals treated. This is a much lower incidence
than was seen in the earlier experiments treating normal tissues in
the region of the pancreas (Mlkvy et al, 1996) and is mainly as a
result of shielding the duodenum during treatment. The perfora-
tions that did occur may have been caused by slipping of the
opaque paper shielding the duodenum, particularly as two of the
three perforations occurred in animals treated with fractionated
light, hence the treatment times were longer. The human
duodenum is much thicker than that in the hamster and is likely to
be much more resistant to perforation. Two preliminary clinical
reports using PDT with Photofrin to treat duodenal and ampullary
tumours showed an encouraging response with no perforations
(Abulafi et al, 1995; Mlkvy et al, 1995). This suggests that it is
likely to be safe to treat lesions in the human pancreas. Bile duct
obstruction was seen in four animals but our previous studies
showed that this was resolved by 7 days (Mlkvy et al, 1996); there
were no perforations and hence it was most likely to be due to
ampullary oedema. If this occurred clinically, it could be relieved
by endoscopic insertion of a biliary endoprosthesis. The diverticu-
losis of the duodenum seen in two animals was unexpected,
perhaps caused by partial obstruction of the distal duodenum, but
had no obvious undesirable consequences. The sealed duodenal
perforations in addition to three laparotomies within a month prob-
ably contributed to the death of two animals before the planned
date of sacrifice. It might have been expected that PDT would
cause an acute pancreatitis and perhaps even lead to pancreatic
cyst formation, but we saw no evidence ofthis. The animals in this
study were only kept alive for a few days but, even in our previous
work (Regula et al, 1994) and in that ofothers (Evrard et al, 1994)
in which animals were kept alive for up to 3 months, no evidence
ofpancreatitis or cyst formation was seen.
Other publications (Mang and Wiemann, 1987; Schroder et al,
1988; Chatlani et al, 1992; Evrard et al, 1994; Regula et al, 1994)
have demonstrated pancreatic tumour necrosis with PDT using the
photosensitizing agents AlSPc, Photofrin, ALA and pheophorbide
A. As the tumour model used here has been shown to share many
characteristics with the human disease (Takiyama et al, 1990), our
results are encouraging for the application of PDT to human
pancreatic cancers. Photofrin has the longest duration of skin
photosensitivity, which can last for months, in contrast tojust 1-2
days with ALA. AlSPc and pheophorbide A cause few skin prob-
lems in animals (Tralau et al, 1989; Evrard et al, 1994), but there
are no clinical data; mTHPC does make patients photosensitive for
2-3 weeks.
Several factors determine the depth of necrosis produced; these
include the dose of photosensitizing drug, the light dose and the
light delivery geometry. Another is the wavelength of light used.
AlSPc has a strong absorption peak at 675 nm, giving better light
penetration of tissue than is possible at shorter wavelengths.
Pheophorbide A and mTHPC absorb less strongly at 665 nm and
652 nm, respectively, whereas ALA/PPIX and Photofrin require
excitation at 630-635 nm, which corresponds to relatively weak
absorption peaks. It is difficult to compare the published results
with all these photosensitizers as the geometry ofthe light delivery
systems used and the ways ofquantifying tissue necrosis differed,
but ultimately the aim is to destroy as much tumour as possible
with the minimum number of treatment sites and no unacceptable
damage to adjacent normal tissues. The maximum diameter ofthe
zone of necrosis in tumour with light delivered via a single fibre
touching the tumour surface (as used for ALA, AlSPc and
mTHPC) was greatest using mTHPC (up to 12.4 mm). This was
achieved using light fractionation and, using continuous light, the
value (8.5 mm) was similar to that found with ALA (8 mm,
Regula et al, 1994) and AlSPc (8 mm, Chatlani et al, 1992). The
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choice of treatment time after administration also varies consider-
ably between these sensitizers: 3-4 h for ALA/PPIX compared
with up to several days for mTHPC. We compared the efficacy of
mTHPC at 2 and 4 days and found that larger lesions were present
for 4 days in agreement with the results of the fluorescence
microscopy studies. However, the correlation between PDT effi-
cacy and sensitizer pharmacokinetics, whether measured using
fluorescence microscopy or radiolabelling, should not be over-
stated as the microscopic distribution of the sensitizer will vary
after administration, with differing amounts present in tumour
compartments (Chatlani et al, 1992); differential uptake by
macrophages may also be an important factor. Even if similar
mean concentrations are found at different times after administra-
tion, this does not necessarily translate into similar PDT efficacy
as the microscopic distributions may be significantly different.
So far, only one randomized, controlled survival study has been
reported (Regula et al, 1994), but this did show a significantly
increased survival time for hamsters with transplanted pancreatic
cancers treated with PDT using ALA compared with untreated
controls. Although the study from Evrard et al (1994) using
Pheophorbide A was not randomized, their animals also survived
longer than would have been expected from historical controls.
The present work did not include a survival study, but as the diam-
eter of PDT necrosis in these hamster cancers using mTHPC with
a single-fibre treatment point was at least as large as that in the
ALA study, it is likely that a survival advantage could be shown.
Much has been written about the selectivity ofuptake ofphoto-
sensitizers in malignant tissue. In most tissues, the ratio ofphoto-
sensitizer concentration in tumour to that in the adjacent normal
tissue in which the tumour arose rarely rises above 2-3:1, and it is
difficult to get any tumour necrosis without damage to adjacent
normal tissue if both are exposed to the same light dose (Bown,
1990). The highest ratio of photosensitizer concentration between
pancreatic cancer and normal pancreas reported, i.e. 13.5, is with
pheophorbide A (Evrard et al, 1994). The figures for the other
photosensitizers are 8:1 for protoporphyrin IX (the active deriva-
tive ofALA) obtained by Regula et al (1994), but only 1.2:1 in the
present study with mTHPC using the same transplanted tumour
model. A ratio of 3:1 for AlSPc (Chatlani et al, 1992) and
Photofrin (Schroder et al, 1988) was obtained using a chemically
induced autochthonous pancreatic tumour model. An interesting
finding common to all studies is that normal pancreas appears to
be relatively resistant to PDT. Ithas been postulated that there may
be a singlet oxygen scavenger in normal pancreas (perhaps
glutathione) that is not present in pancreatic cancers and that
protects the normal areas from PDT damage (Chatlani et al, 1992).
If this different mechanism for therapeutic selectivity is true, it
could be possible to obtain selective tumour necrosis even without
higher levels of the photosensitizing agents in tumour. In our
studies using 0.3 mg kg' mTHPC and a continuous light dose of
50 J delivered via a single fibrejusttouching the tissue surface, the
diameter of necrosis in normal pancreas was 4 mm (Mlkvy et al,
1996) compared with 8.5 mm in tumour, as reported in this paper.
Fractionation of the light dose used for PDT is attracting
increasing interest. Two reports described enhancement of PDT
necrosis of animal tumours using ALA (van der Veen et al, 1994)
and HpD (Pe et al, 1994) with treatment breaks of 60-90 min
between fractions. More dramatic effects were described by
Messman et al (1995) using ALA with intervals of only a few
minutes between light fractions; they showed that under appro-
priate circumstances, the area ofnecrosis in normal colon could be
increased by afactorof7. Hua et al (1995) achieved a significantly
increased tumour (transplanted rat mammary adenocarcinoma)
doubling time using ALA when the light dose was modulated in a
30 s on/off protocol. Using mTHPC or Photofrin, van Geel et al
(1996) found that only certain fractionation schedules were effec-
tive in limiting regrowth of a RIF-1 tumour model: for mTHPC,
discontinuous irradiation with the 30 s on/off protocol proved
effective at a fluence rate of 100 mW cm-2. The most likely mech-
anism is that the dark intervals are permitting reoxygenation ofthe
partly treated tissue. In ourprevious study with mTHPC on normal
pancreas, we obtained an increase in lesion size of about 30% by
dividing the light dose into fourfractions separated by 1-min inter-
vals (Mlkvy et al, 1996). Our current work on a tumour model has
shown that, with a dose of0.3 mg kg-' mTHPC 4 days before PDT
with a total light dose of 50 J, the average diameter of necrosis
could be increased from 8.5 mm with continuous light to 12.1 mm
with fractionation, an increase of about 40%. This could perhaps
be improved further by changing the point during treatment at
which the break is made and the duration ofthe break.
Few studies have been undertaken of PDT in other solid rather
than hollow organs, but recent reports of experiments in the
normal canine prostate show that zones ofnecrosis up to 24 mm in
diameter can be produced around single fibres placed interstitially
after photosensitization with mTHPC (Chang et al, 1996). Using
AlSPc, the maximum lesion size in the prostate was only 12 mm
(Chang et al, 1997). From our clinical studies on tumours of the
mouth (unpublished data), it is becoming clear that deep PDT
effects can be achieved with remarkably low light doses (5-
20J cm-2), which further indicates that mTHPC is a valuable
photosensitizer for producing larger volumes of necrosis with
low light doses and, consequently, short treatment times.
These studies suggest that PDT is a safe technique for treating
cancers in the pancreas with any ofthe photosensitizers discussed
here. Selectivity of tumour uptake was least using mTHPC, but
this is not critical. The attraction of mTHPC is the possibility of
producing larger volumes of necrosis around each treatment site
with low light doses and hence shortening treatment times. In
patients with small cancers localized to the pancreas who are unfit
for pancreatectomy because oftheir general medical condition and
for whom there are no other therapeutic options, it would now
seem justified to consider pilot clinical studies if the free flow of
bile is protected by a biliary endoprosthesis. Laser fibres could be
positioned in the tumour through needles placed percutaneously
underultrasound orcomputerized tomography (CT) guidance, as is
done routinely in the management ofsmall liver tumours (Amin et
al, 1993), and the results assessed by contrast-enhanced CT scans.
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